Herein, using a humanized murine immunotherapy model, we demonstrated that ILT4 antagonism enhanced the efficacy of PD-L1 inhibitor in EGFR wild-type NSCLC. This evidence concerns the gene LILRB2 and non-small cell lung carcinoma.